SCHEMBL4154673

SCHEMBL4154673

CCNC(=O)c1cccc(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
P2RX7 Q99572 1/20 0.55
MAPT P10636 1/20 0.55
GPR139 Q6DWJ6 2/20 0.55
ATM Q13315 1/20 0.55
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
GRM5 P41594 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9713054 0.87 SMN1; SMN2 (0.67) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL6360274 0.86 L3MBTL1 (0.69) ALDH1A1MEN1KMT2ATP53POLB
SCHEMBL6358483 0.83 SMN1; SMN2 (0.79) MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL27815909 0.83 MAPT (0.50) ALDH1A1MEN1KMT2ACYP1A2CYP2D6
SCHEMBL4820100 0.83 GRM5 (0.58) ALDH1A1MEN1KMT2ATP53CYP1A2
SCHEMBL5925632 0.83 MEN1 (0.57) ALDH1A1MEN1KMT2AMAPTPKM
SCHEMBL6543983 0.82 SMN1; SMN2 (0.71) MEN1KMT2ASMN1; SMN2
SCHEMBL47363 0.82 CA1 (0.57) ALDH1A1MEN1KMT2ATP53CYP1A2
SCHEMBL3815582 0.82 P2RX7 (0.55) ALDH1A1MEN1KMT2ATP53CYP1A2
SCHEMBL11350516 0.82 P2RX7 (0.55) ALDH1A1MEN1KMT2ATP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858879-B2 PARG inhibitors and method of use thereof CITY OF HOPE (US) 2024-01-02 US disclosed
WO-2023125473-A1 INDOLINE COMPOUNDS AND DERIVATIVES THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国药科大学 2023-07-06 WO disclosed
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2022-01-06 US disclosed
CN-112299938-B Method for preparing amine compound by reducing amide compound 中国科学院兰州化学物理研究所 2021-12-28 CN disclosed
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
CN-112299938-A Method for preparing amine compound by reducing amide compound 中国科学院兰州化学物理研究所 2021-02-02 CN disclosed
EP-2348023-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP disclosed
CN-103265442-A Novel pleuromutilin derivatives, as well as preparation method and anti-tumour application thereof BEIJING INST TECHNOLOGY 2013-08-28 CN disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-4160095-A PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-07-03 US disclosed
US-4157441-A PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-06-05 US disclosed
US-4151351-A PROSTAGLANDINS, ANTIINFLAMMATORY THE UPJOHN COMPANY (US) 1979-04-24 US disclosed
US-4131738-A 6-Hydroxy-PGE1 compounds THE UPJOHN COMPANY (US) 1978-12-26 US disclosed
US-4128713-A 6,7-Didehydro-PGI1 compounds THE UPJOHN COMPANY (US) 1978-12-05 US disclosed
US-4126744-A PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS THE UPJOHN COMPANY (US) 1978-11-21 US disclosed
US-4112224-A PROSTAGLANDIN THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4109082-A PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS THE UPJOHN COMPANY (US) 1978-08-22 US disclosed
US-4100192-A Inter-phenylene-PG amides THE UPJOHN COMPANY (US) 1978-07-11 US disclosed
US-4097489-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF PARG, PARP12, PARP15 ALDH1A1 1104/4885MEN1 1638/4885KMT2A 1009/4885
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 ALDH1A1 284/4885MEN1 2323/4885KMT2A 155/4885
US-11858879-B2 PARG inhibitors and method of use thereof PARG, PARP12, PARP15 ALDH1A1 1104/4885MEN1 1638/4885KMT2A 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.